Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LXRX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sotagliflozin (LX4211) FDA approved May 2023 · Inpefa |
Type 1 Diabetes (T1D) | Phase 3 · NCT07211802 | Not yet recruiting |
| Telotristat Etiprate | Carcinoid Syndrome | Phase 3 · NCT02026063 | Completed |
| Metformin | Type 2 Diabetes Mellitus | Phase 3 · NCT03066830 | Completed |
| Sulfonylurea Antidiabetic Agent | Type 2 Diabetes Mellitus | Phase 3 · NCT03066830 | Completed |
| Oral Antidiabetes Drugs (OADs) | Type 2 Diabetes Mellitus | Phase 3 · NCT03285594 | Completed |
| LX9211 | Diabetic Peripheral Neuropathic Pain | Phase 2 · NCT06203002 | Completed |
| Nab-paclitaxel | Locally Advanced Unresectable Pancreatic Adenocarc | Phase 2 · NCT03910387 | Completed |
| Octreotide LAR Depot | Carcinoid Syndrome | Phase 2 · NCT00853047 | Completed |
| Volagidemab | Type 1 Diabetes | Phase 1/2 · NCT05696366 | Active not recruiting |
| LX7101 (0.125%) | Primary Open-angle Glaucoma | Phase 1/2 · NCT01528111 | Completed |
| Treatment C Digoxin + 400 mg LX4211 admi | Healthy | Phase 1 · NCT02300350 | Completed |
| Treatment C (rosuvastatin + 400 mg LX421 | Healthy | Phase 1 · NCT02300363 | Completed |
| Treatment B LX4211 | Healthy | Phase 1 · NCT02300350 | Completed |
| Treatment B (LX4211) | Healthy | Phase 1 · NCT02300363 | Completed |
| Treatment A digoxin | Healthy | Phase 1 · NCT02300350 | Completed |
| Treatment A (rosuvastatin) | Healthy | Phase 1 · NCT02300363 | Completed |
Also used in these trials (approved or third-party drugs, not LXRX's own candidates): Empagliflozin, Glimepiride, Insulin Glargine, Telotristat Ethyl, Gemcitabine Hydrochloride, Omeprazole, Midazolam Hydrochloride, Famotidine, Octreotide Acetate, Apixaban.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LXRX holds $190.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $12M/quarter from operations, an estimated runway of 47.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LXRX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LXRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →